Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) | MicrobiomeTrials
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-03-17Est. Completion: 2033-01-01
Enrollment target: 75 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States